Loading organizations...
Key people at Torque3.
Torque3 develops a neurorehabilitation solution combining deeply immersive simulations and advanced robotics. Its platform enhances neuroplasticity through experience-dependent, multimodal integration, utilizing proprietary hardware and software where all mechanical functions are computer-controlled and robotic. This system leverages a suite of technologies to deliver task-oriented therapy, allowing patients to engage their entire body, senses, and cognitive abilities during treatment.
Founded in 2016 by David Ellzey, Torque3 emerged from the insight that recovery for stroke and other neurological impairments could be significantly improved by leveraging established research in immersive stimulation and robotic assistance. Ellzey, an entrepreneur and innovator in neurorehabilitation, recognized the potential to create a sophisticated system that integrated these technologies with uncompromising design and implementation.
The company primarily serves patients, caregivers, and rehabilitation clinics. Torque3 envisions providing patients with significantly better recovery outcomes, reducing the mental health burden on caregivers, and improving efficiency for therapists by streamlining tedious tasks. Its long-term goal is to make high-quality, data-driven neurorehabilitation accessible and effective, ultimately transforming recovery pathways.
Torque3 is a neurorehabilitation company developing an advanced platform that combines immersive simulations, robotic assistance, and task-oriented therapy to enhance recovery outcomes for stroke survivors and other neurological conditions like traumatic brain injuries (TBI), dementia, and Parkinson's disease[1][2][3][5]. The Torque3 platform (TOT+) targets plateaued patients in partner clinics, delivering equipment sales, licensing, and management fees while generating real-time data for progress tracking and neuroplasticity enhancement; it has secured initial clinic deals projecting over $2.5 million in revenue this year and $25 million over three years[1][2][3]. Serving stroke survivors primarily in the US via a network of 16-20 partner clinics (each needing ~120 patients annually), it solves suboptimal recovery rates by creating an "illusion of presence" and "perception of risk" through multi-sensory engagement, with early testing showing significantly better outcomes and a path to insurance reimbursement via new CPT codes[1][2][3][5].
Torque3 emerged from decades of research on immersive stimulation and robotics for stroke recovery, with the company leveraging this foundation for a "uncompromising" platform design[3][5]. Founded by a CEO who is a veteran of three prior ventures, the team includes executive board members and medical advisors with commercialization expertise; the founder leads efforts to ramp up production and clinic partnerships[1][2]. Key early traction includes securing the first two partner clinics (driving >$2.5M revenue this year), closing more deals imminently, and raising $5.54M across five rounds, culminating in a $3.15M Seed VC-II on December 9, 2022; headquartered in San Jose, CA (with ties to Utah), it's now filing additional patents and bridging to Series A[2][3][4][7].
Torque3 rides the wave of neurotech and rehab robotics, capitalizing on 30+ years of research proving immersive, multi-sensory therapy boosts neuroplasticity amid rising stroke/TBI incidence (e.g., millions affected yearly in the US)[3][5]. Timing aligns with maturing robotics (lower costs, better AI integration) and post-pandemic demand for outpatient neurorehab, where traditional therapy plateaus quickly; market forces like aging populations and insurance pushes for efficacy data favor its data-driven, objective platform[1][2][3]. It influences the ecosystem by pioneering private-pay clinics as a reimbursement bridge, potentially standardizing TOT+ and enabling exits/acquisitions in a sector seeing consolidation (e.g., by medtech giants)[2].
Torque3 is poised for Series A this year after its $500K bridge funding, with 16+ clinics, $25M three-year revenue, and CPT code pursuit triggering acquisition liquidity[1][2]. Trends like AI-enhanced neuroplasticity, VR/AR rehab adoption, and value-based care will accelerate growth, evolving its influence from niche innovator to ecosystem standard-setter in stroke/TBI recovery. As clinic data builds brand and validates outcomes, expect scaled impact beyond US stroke survivors, cementing its breakthrough in a high-need medtech frontier.
Key people at Torque3.
